What is MMIHS? Megacystis-microcolon-intestinal hypoperistalsis syndrome (MMIHS), also called Berdon syndrome, affects bladder emptying and intestinal movement. Dated syndrome description.
Confidence: the bowel–bladder distinction is established clinical context. Assessment and supportive care require coordinated specialist services. This guide establishes no independent drug, transplant-outcome or supplement ranking and supplies no personal feeding or catheter regimen.
- Both gastrointestinal and urinary care matter; request one coordinated plan.
- An established motility diagnosis does not rule out a new physical obstruction.
- The actual genetic finding matters for counselling; do not apply one inheritance rule to every family.
- Nutrition, venous-line safety, urine drainage and kidney monitoring need separate instructions.
- Urgent illness needs assessment rather than a home feeding, laxative or catheter experiment.
Table of contents
- Evidence summary
- Berdon syndrome: bowel and bladder smooth-muscle dysfunction
- ACTG2 and the limits of a single-gene explanation
- Prenatal findings and the newborn assessment
- Clinical diagnosis, imaging and genetic interpretation
- Bladder drainage and protecting the kidneys
- Urinary-catheter problems and caregiver training
- Feeding, parenteral nutrition and ongoing monitoring
- Venous-line risks, liver findings and serious illness
- Operations, transplantation and medicine review
- Inheritance, supplements and human-evidence limits
- Funding and source roles
- Frequently asked questions
- Sources and funding notes
Evidence summary
Clinical guidance, human outcome research and funding independence answer different questions. The guidance below explains care; it does not independently reproduce the trials behind a medicine or supplement.
| Claim / intervention | Evidence reviewed | Funding / conflicts | Interpretation / limits |
|---|---|---|---|
| Syndrome recognition and genetics | Dated public genetics and selected 2024 specialist overview | Public-library finances differ from chapter publisher; complete chapter and author chain unclosed. | Bowel and bladder assessment; no home genetic or symptom rule. |
| Supportive nutrition and urinary care | Selected paediatric provider education and specialist context | Separate provider accounts; no device or nutrient-product efficacy clearance. | Individual training, monitoring and complication plans. |
| Drug or transplant outcomes | No cleared independent comparison | Historical author commercial interest and source-study receipts unresolved. | No personal eligibility, prognosis estimate or ranking. |
Berdon syndrome: bowel and bladder smooth-muscle dysfunction
The syndrome combines an enlarged bladder, a small-calibre colon and reduced intestinal propulsion. Symptoms can resemble bowel obstruction without a physical blockage. Selected syndrome features.
Ask the team to explain the confirmed findings in plain language: which problem concerns urine drainage, which concerns intestinal movement and whether any additional anatomical problem is present. The term pseudo-obstruction describes a particular clinical problem; it should not become an instruction to dismiss future vomiting or abdominal swelling. Bring the diagnosis, recent investigations and support plan to emergency assessment. A family should not have to infer the seriousness of a new episode from a rare-condition name or a previous reassuring scan.
ACTG2 and the limits of a single-gene explanation
ACTG2 encodes gamma-2 actin involved in smooth-muscle contraction in the bladder and intestine. The dated gene source describes impaired contraction when its function is altered. Selected muscle mechanism.
MMIHS is a syndrome with a genetic assessment, not a synonym for every disorder affecting a hollow organ. Ask which gene and variant were identified and how the result fits the clinical findings. A mechanism explains why an organ may not move or empty normally; it does not establish the suitability of a marketed motility product. Nor should a laboratory finding alone be treated as a forecast of every complication. Request the specialist’s interpretation of any uncertain variant and whether a different or overlapping syndrome needs consideration.
Prenatal findings and the newborn assessment
Some features, including an enlarged bladder, may be recognized on prenatal ultrasound. The older description also recognizes associated intestinal malrotation in some patients. Selected prenatal and anatomical context.
An antenatal finding needs assessment of its cause and implications; this article cannot identify a syndrome from a scan or decide a pregnancy or delivery plan. Families can ask what is known, what remains uncertain, which specialist services should be involved and how the newborn will be assessed. Request a written plan for communicating prenatal findings to the neonatal team. After birth, describe vomiting, abdominal changes, feeding difficulties and urine passage promptly. Do not assume that the absence of a family history, one incomplete scan or a provisional name excludes a serious bowel or urinary problem.
Clinical diagnosis, imaging and genetic interpretation
Selected 2024 overview assessment includes bowel/urinary imaging, functional testing and genetics. Diagnostic scope.
Ask what each proposed investigation is intended to distinguish and how its result would change care. Physical obstruction, impaired propulsion and urinary drainage problems need their own explanations. The team should explain whether a test is diagnostic, supportive or aimed at assessing a complication. No universal scan sequence, contrast dose, tissue-test requirement or result cutoff is provided here. Obtain advice on preparing for the actual procedure and which medicines or nutritional support need review. If a genetic test is negative or uncertain, ask what that result can and cannot exclude rather than assuming that all clinical concerns have disappeared.
Bladder drainage and protecting the kidneys
Selected care goals include bladder decompression and kidney protection. Bladder-care goals.
Ask who leads the urinary plan, how adequacy of drainage is assessed and how kidney results will be followed. A urinary catheter, a surgical drainage opening and a venous nutrition line serve different purposes; caregivers need training for each device actually used. Request the exact contact route for reduced or absent urine, new pain, fever, leakage or a catheter problem. This review does not select an operation, a catheter type or size, an insertion technique or an emptying interval. Do not copy another child’s urinary equipment instructions onto the care plan.
Urinary-catheter problems and caregiver training
CUH’s paediatric suprapubic-catheter leaflet recognizes infection, blockage, displacement and leakage. It advises contact for drainage problems and clinical review of relevant fever. Selected catheter safety context.
These are general safety principles for a specific catheter route, not evidence that every patient with MMIHS should have that device. The treating team must explain the actual route and what caregivers have been trained to do. Obtain written instructions for a catheter that is not draining or has moved, and seek prompt professional advice when those instructions are unclear. This article supplies no reinsertion, flushing, valve, dressing or antibiotic procedure. The leaflet’s general drinking, fruit and constipation suggestions are not transferred to a child with intestinal failure or an individual fluid restriction.
Feeding, parenteral nutrition and ongoing monitoring
The dated syndrome description recognizes variable intravenous nutritional requirements. CUH explains paediatric parenteral nutrition when enteral intake is inadequate, with growth and laboratory monitoring. Dated nutrition context; Selected support and monitoring roles.
Request the purpose of every feeding route and the current plan for energy, fluid and nutrient needs. Nutrition adequacy and urine drainage are separate clinical questions, even when both affect daily care. The responsible team should explain which results it monitors, who receives them and who may adjust support. No feed recipe, infusion volume, pump setting or personal weaning rule is prescribed here. Ask what to do when a feed or infusion cannot be given, supplies are interrupted or equipment fails, and who can be reached outside clinic hours.
Venous-line risks, liver findings and serious illness
CUH’s general home-PN information identifies line infection, blockage and thrombosis, alongside specialist monitoring. Its adult equipment procedures are not instructions for an infant. Selected general line-risk principles.
If intravenous support is used, request practical training for the actual catheter and pump, and an emergency plan for fever, leakage, displacement or equipment failure. Ask how liver findings and nutritional complications will be assessed rather than attributing every abnormal result automatically to one cause. Do not manipulate a line or interrupt prescribed support based on an online troubleshooting sequence. Unusual drowsiness or reduced urine can require urgent assessment; breathing difficulty, collapse, blue or grey colour or difficulty waking a child requires emergency help. NHS dehydration warnings; NHS emergency warnings.
Use the local emergency route; UK guidance uses 999 for emergencies. Tell the assessing team about the diagnosis, nutritional and urinary devices and recent changes. Do not wait for all warning signs or a routine review.
Operations, transplantation and medicine review
The overview describes selected decompression procedures and intestinal or multivisceral transplant consideration for serious nutritional-support complications. It cautions about medicines reducing bowel or bladder motility. Bounded procedure and medicine context.
Ask which specific problem a proposed procedure addresses: an anatomical blockage, decompression, delivery of nutrition or a complication of support. The syndrome name alone is not a transplant recommendation or a guarantee of a particular outcome. Obtain the current service’s explanation of alternatives, uncertainties, monitoring and evidence finances. Share all medicines and nonprescription products with the team; do not stop a prescription or begin a laxative from this article. A medicine-risk review is an individual clinical decision, not a blanket ban on every treatment affecting digestion or urinary symptoms.
Inheritance, supplements and human-evidence limits
The 2024 overview recognizes typically dominant ACTG2 and dominant ATP2B4-related disease, with recessive causes in other named genes; ACTG2 cases can be new or inherited. Selected updated inheritance context.
Genetic counselling must use the actual findings and family information. Ask what testing can establish, how uncertain results will be handled and which relatives may need advice. This guide gives no personal recurrence percentage or reproductive-testing recommendation. No independently cleared supplement benefit correcting MMIHS is established here. Disclose proposed supplements and all ingredients to the care team; NCCIH’s dated precautions support that discussion. Generic supplement precautions.
Animal and cell experiments are excluded from patient-benefit conclusions. Human comparative claims require the original population, intervention, comparator, follow-up, harms and complete funder/author chain. A public-library URL does not identify the chapter’s publisher or clear those interests.
Funding and source roles
Research funding at a glance
19 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
Clinical descriptions, care-context sources and financial originals have distinct roles in the table. The author’s separately dated interest record is not proof that a company commissioned the chapter. Unclosed chapter, employer and supporting-study receipts prevent a cleared independent comparative-treatment verdict.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| NLM MMIHS, October 2017 | Separate budget, dated gift authority and editorial process. Page/reviewer and cited-study finances unclosed. | United States; NLM/NIH/HHS, Bethesda, Maryland. | Tier 2 public genetics context, provisional. | C provisional — scientific review favors accuracy; dated education and unresolved contributor/study interests limit use. |
| NLM ACTG2 gene, December 2017 | Separate budget, dated gift authority and editorial process. Page/reviewer and cited-study finances unclosed. | United States; NLM/NIH/HHS, Bethesda, Maryland. | Tier 2 public genetics context, provisional. | C provisional — scientific review favors accuracy; dated education and unresolved contributor/study interests limit use. |
| Ambartsumyan: GeneReviews MMIHS overview, August 2024 | Chapter allocation unstated. Separate author interests, publisher accounts and programme history. Employer/study receipts unclosed. | United States; UW publisher and Seattle Children’s author, Seattle; NLM host Bethesda. | Tier 3 historically connected author. | C provisional — original read; dated care synthesis, financial gaps. |
| NASPGHAN member author declarations, September 2022 | Ambartsumyan reports Takeda consulting or sponsored-CME personal income for March–December 2022; other categories answered no. Separate date, not proof of chapter payment. | United States; author Seattle, Washington; society-hosted declaration. | Tier 3 historical personal-financial original. | B provisional — actual page 7 and scope read; self-reported category, later contracts and chapter allocations unclosed. |
| UW audited financial report, 2025 | Patient/tuition, federal/state-local/nongovernmental grants and services; nonoperating appropriations, gifts and investments separate. Chapter and Seattle Children’s allocations unclosed. | United States; University of Washington, Seattle; Washington State jurisdiction. | Tier 3 statutory institutional fiscal original. | B provisional — actual 90-page report, main statements/entity notes read; audit supports accuracy, budget/service incentives remain. |
| UW GeneReviews founder profile | Identifies NIH programme grants/contracts during the founder’s 1996–2017 leadership. No current award or condition-page allocation inferred. | United States; UW Pediatrics, Seattle, Washington. | Tier 3 historical programme/process self-report. | B provisional — actual profile read; institutional reputation incentives and current receipt gaps remain. |
| CUH child parenteral nutrition, September 2024 | Separate publisher financial profile. Page, contributor and study allocations unclosed. | United Kingdom; Cambridge University Hospitals, Cambridge, England. | Tier 2 care context, provisional. | C provisional — clinical accountability favors accuracy; service/reputation incentives and unclosed interests remain. |
| CUH home parenteral nutrition, May 2026 | Separate publisher financial profile. Page, contributor and study allocations unclosed. | United Kingdom; Cambridge University Hospitals, Cambridge, England. | Tier 2 care context, provisional. | C provisional — clinical accountability favors accuracy; service/reputation incentives and unclosed interests remain. |
| NHS serious childhood illness, August 2026 | Separate publisher financial profile. Page, contributor and study allocations unclosed. | United Kingdom; national NHS website, distinct from trusts. | Tier 2 care context, provisional. | C provisional — clinical accountability favors accuracy; service/reputation incentives and unclosed interests remain. |
| NHS dehydration, May 2026 | Separate publisher financial profile. Page, contributor and study allocations unclosed. | United Kingdom; national NHS website, distinct from trusts. | Tier 2 care context, provisional. | C provisional — clinical accountability favors accuracy; service/reputation incentives and unclosed interests remain. |
| NHS national content policy, October 2022 | DHSC funding and no advertising/corporate sponsorship stated in its own policy. Full current contributor, source-study and page receipts unclosed. | United Kingdom; national NHS website. | Tier 3 financial/editorial self-report. | B provisional — disclosed safeguards and accountability; review due October 2025 passed. This policy does not identify provider-trust receipts. |
| CUH audited annual accounts, 2025–26 | NHS commissioners, private/overseas care, research/training, gifts, rent/services; NIHR infrastructure and industry/charity partnerships separately described. Page/reviewer allocations unclosed. | United Kingdom; Hills Road, Cambridge, England. | Tier 3 institutional financial report. | B provisional — statutory audited reporting favors accuracy; provider/budget interests remain. Notes 2.1–2.3 and partnership discussion read; no source-trial clearance. |
| NCCIH supplement precautions, January 2019 | Separate appropriations history and gift authority. Page/contributor and cited-study receipts unclosed. | United States; NIH/HHS, Bethesda, Maryland. | Tier 2 public safety context, provisional. | C provisional — scientific accountability favors accuracy; dated summary and unclosed trial finances do not establish condition-specific benefit. |
| NCCIH appropriations history through FY2024 | Historical congressional appropriations table. No current-year enacted amount, accepted donor ledger or condition-page allocation inferred. | United States; NIH/HHS federal budget jurisdiction. | Tier 3 institutional fiscal reporting. | B provisional — transparent dated table favors accuracy; budget/mission incentives and missing page/trial allocations remain. |
| NCCIH Gift Fund authority and contact | Permitted gifts to public research agency; authority is not proof of a named accepted donor or sponsored page. Full receipt allocation unclosed. | United States; 31 Center Drive, Bethesda, Maryland. | Tier 3 institutional financial self-report. | B provisional — explicit process/contact supports accuracy; fundraising/mission interests and donor gaps remain. |
| NLM budget justification, FY2027 | Congressional budget authority; FY2026 enacted and FY2027 requested columns are distinct. Whole-library support, not page receipts. | United States; NLM/NIH/HHS, Bethesda, Maryland. | Tier 3 institutional fiscal original. | B provisional — actual 20-page table/programme text read; public accountability helps, budget interests and page allocations remain. |
| HHS gift-authority memorandum, August 2002 | Dated legal authority identifies NLM gift acceptance and outside co-sponsorship; no named current gift or page allocation inferred. | United States; federal HHS/NIH authority. | Tier 3 historical financial-authority original. | B provisional — actual four-page original read; age, implementation and complete donor receipts remain gaps. |
| NLM genetics editorial process, October 2023 | Institutional writing/selection process; separate appropriations and historical gift authority above. Individual interests unclosed. | United States; 8600 Rockville Pike, Bethesda, Maryland. | Tier 3 process and identity self-report. | B provisional — actual body/date read; review supports accuracy but does not clear finances or provide detailed care algorithms. |
| CUH paediatric suprapubic catheter information, January 2024 | Separate publisher financial profile. Page, contributor and study allocations unclosed. | United Kingdom; Cambridge University Hospitals, Cambridge, England. | Tier 2 care context, provisional. | C provisional — clinical accountability favors accuracy; service/reputation incentives and unclosed interests remain. |
Frequently asked questions
Is Berdon syndrome a separate illness from MMIHS? Berdon syndrome is an alternative name used for MMIHS in the cited clinical sources; this guide covers the combined syndrome.
Does pseudo-obstruction mean new vomiting is harmless? No. Seek assessment according to the child’s urgent-care plan rather than assigning a new episode to an old label.
Does every patient need identical feeding and urinary equipment? The specialist services should explain the actual support requirements and the reasons for each device or change.
Can a transplant solve every bowel and bladder issue? Ask the transplant and urology teams to identify the problems addressed and the remaining care needs. This review makes no universal cure claim.
Can I use a general constipation or catheter leaflet as my regimen? Use the team’s individual instructions. General food, fluid and device procedures may not fit intestinal failure or the actual urinary route.
Sources and funding notes
Actual NLM syndrome body updated 1 October 2017; ACTG2 body 1 December 2017. Full 14-page GeneReviews original updated 1 August 2024, selected clinical and chapter-note passages read; older blanket de-novo inheritance not adopted. NASPGHAN actual 2022 author declaration is separately dated. Numerical case/prognosis estimates, oversimplified differential-table exclusions, generic catheter drinking/fruit advice and home device procedures excluded. CUH catheter leaflet approved 8 January 2024, child PN 13 September 2024, home PN 12 May 2026. Source-specific financial records do not clear underlying studies.
- NLM MMIHS, October 2017 — Selected recognition; older universal inheritance/prognosis language excluded.
- NLM ACTG2 gene, December 2017 — Selected smooth-muscle mechanism; older all-de-novo wording excluded.
- Ambartsumyan: GeneReviews MMIHS overview, August 2024 — Diagnosis, bladder, inheritance and procedure context.
- NASPGHAN member author declarations, September 2022 — Historical author interest only; no clinical findings.
- UW audited financial report, 2025 — Publisher financial routes only; not host, employer or trial clearance.
- UW GeneReviews founder profile — Historical programme route only.
- CUH child parenteral nutrition, September 2024 — Selected intravenous-nutrition and monitoring roles; personal schedules excluded.
- CUH home parenteral nutrition, May 2026 — Selected general line-risk principles; adult equipment instructions not transferred to infants.
- NHS serious childhood illness, August 2026 — Emergency warning signs.
- NHS dehydration, May 2026 — Selected urgent dehydration signs; no fluid prescription.
- NHS national content policy, October 2022 — Dated national website provenance only.
- CUH audited annual accounts, 2025–26 — Actual 197-page original, selected financial notes and partnerships.
- NCCIH supplement precautions, January 2019 — Generic interaction/product disclosure only.
- NCCIH appropriations history through FY2024 — Historical fiscal route only.
- NCCIH Gift Fund authority and contact — Gift authority and headquarters only.
- NLM budget justification, FY2027 — Enacted/request distinction only.
- HHS gift-authority memorandum, August 2002 — Historical permission only.
- NLM genetics editorial process, October 2023 — Education scope and headquarters only.
- CUH paediatric suprapubic catheter information, January 2024 — Selected catheter risk/contact principles; no device choice, manipulation or fluid schedule.
Educational information reviewed 4 October 2026. This guide supports an informed clinical discussion; it does not diagnose an individual or provide a personal treatment regimen.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.